Autor: |
Robert P. Rehfuss, Paul Levesque, Juliang Zhu, Arvind Mathur, Dietmar A. Seiffert, Bang-Chi Chen, Rejean Ruel, Laura Price, Yufeng Wang, Mary F. Malley, Xue-Qing Chen, Wu Yang, Ji Hua, Tammy C. Wang, William A. Schumacher, Yajun Liu, Dauh-Rurng Wu, Silvi A. Chacko, Jeffrey S. Bostwick, Charles G. Clark, Danshi Li, Patrick Y.S. Lam, Henry S. Wong, Anne B. Stewart, Dawn Sun, Ruth R. Wexler, Hong Shen, Sheldon Hiebert, Christine Huang, Ling Li, Jeon Yoon T, Carl Thibeault, Jennifer X. Qiao |
Rok vydání: |
2013 |
Předmět: |
|
Zdroj: |
Bioorganicmedicinal chemistry letters. 24(5) |
ISSN: |
1464-3405 |
Popis: |
Spiropiperidine indoline-substituted diaryl ureas had been identified as antagonists of the P2Y1 receptor. Enhancements in potency were realized through the introduction of a 7-hydroxyl substitution on the spiropiperidinylindoline chemotype. SAR studies were conducted to improve PK and potency, resulting in the identification of compound 3e, a potent, orally bioavailable P2Y1 antagonist with a suitable PK profile in preclinical species. Compound 3e demonstrated a robust antithrombotic effect in vivo and improved bleeding risk profile compared to the P2Y12 antagonist clopidogrel in rat efficacy/bleeding models. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|